Pfizer Teminates the Deal to Develop Giroctocogene Fitelparvovec for Hemophilia A with Sangamo Therapeutics

Shots:

• Sangamo regains rights to giroctocogene fitelparvovec (gene therapy for hemophilia A) as Pfizer ends their collaboration (effective Apr 21, 2025) & decids not to file BLA or MAA to pursue commercialization. Sangamo plans to seek a new partner
• The drug is in P-III (AFFINE) trial involving 75 adult males with severe hemophilia A who completed a min 6mos. of routine FVIII replacement prophylaxis. Pfizer (in Jul 2024) reported that the trial met its 1 & 2EPs, showing superiority in reducing mean total ABR (1.24 vs 4.73) from wk.12 to at least 15mos. follow up
• In addition, Sangamo plans to recruit for P-I/II trial of ST-503 for idiopathic small fiber neuropathy by mid-2025 & CTA filing for prion disease program in Q4’25, pending additional funding

Ref: Sangamo Therapeutics | Image: Sangamo Therapeutics

Related News:- Astellas and Sangamo Therapeutics Partner for Administering Genomic Therapies Targeting Neurological Disorders

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com